Company: HURA
Filing Date: 2025-05-06
Form Type: S-4/A
Source: 0001193125-25-113920
Chunk: 822

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-05-06
Form: S-4/A
Chunk 822
---
 its subsequent events from December 31, 2023, through the date these condensed consolidated interim financial statements were issued and has determined that there are no subsequent events requiring disclosure in these condensed consolidated interim financial statements other than the items noted below.

<div align='center'>F-65</div>

Kintara Therapeutics, Inc. Notes to Condensed Consolidated Interim Financial Statements (Unaudited) December 31, 2023 (expressed in US dollars and in thousands, except par value and per share amounts, unless otherwise noted) Proceeds from the Company’s At-The-Market(“ ATM” ) facility From January 1, 2024 until February 12, 2024, the Company raised $ 6,108in net proceeds from the sale of 28,870shares of its common stock under the ATM Facility. Final CRO payment On January 9, 2024, the Company paid $ 400pursuant to the termination agreement with the CRO (Note 3). Initiation of REM-001Clinical Study On February 12, 2024, the Company announced the initiation of a REM-001 15-patientclinical trial in CMBC patients. Opt-OutNotice to Valent for VAL-083 On February 13, 2024, the Company sent an Opt-OutNotice to Valent under the Valent Assignment Agreement whereby the Company assigned all rights, title, and interest in and to the patents for VAL-083to Valent. As a result, the Company granted Valent a non-exclusive,fully-paid, royalty-free, perpetual, worldwide and non-transferablelicense, subject to limited exceptions. The Company is entitled to receive royalties from Valent’s subsequent commercialization equal to 5% of Valent Net Sales (as defined in the Valent Assignment Agreement). F-66 REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM To the Stockholders and the Board of Directors TuHURA Biosciences, Inc. Opinion on the Financial Statements We have audited the accompanying consolidated balance sheets of TuHURA Biosciences, Inc. (the “Company”) as of December 31, 2024 and 2023, the related consolidated statements of operations, stockholders’ (deficit) equity, and cash flows for the years then ended, and the related notes to the consolidated financial statements (collectively the “financial statements”). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 202